These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28918459)

  • 1. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients.
    Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
    Cancer Immunol Immunother; 2018 Jan; 67(1):79-87. PubMed ID: 28918459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
    Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
    J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
    Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
    Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
    Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
    Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
    Farace F; Gross-Goupil M; Tournay E; Taylor M; Vimond N; Jacques N; Billiot F; Mauguen A; Hill C; Escudier B
    Br J Cancer; 2011 Mar; 104(7):1144-50. PubMed ID: 21386843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Zhou X; Fu G; Zu X; Xu Z; Li HT; D'souza A; Tulpule V; Quinn DI; Bhowmick NA; Weisenberger DJ; Liang G; Chen J
    Urol Oncol; 2022 Jan; 40(1):12.e13-12.e22. PubMed ID: 34454823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
    Xia Y; Liu L; Xiong Y; Bai Q; Wang J; Xi W; Qu Y; Xu J; Guo J
    BMC Cancer; 2017 Jan; 17(1):70. PubMed ID: 28114889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
    Verma J; Jonasch E; Allen P; Tannir N; Mahajan A
    Cancer; 2011 Nov; 117(21):4958-65. PubMed ID: 21484781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients.
    Qu Y; Lin Z; Qi Y; Qi Y; Chen Y; Zhou Q; Zeng H; Liu Z; Wang Z; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Zhu Y; Xu L; Chen L; Zhang P; Zhang W; Dai B; Liu L; Xu J; Guo J
    Urol Oncol; 2020 Apr; 38(4):293-304. PubMed ID: 31889617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
    Chen X; Yao J; Liu L; Zheng W; Hu X; Zhu Y; Wang H; Guo J
    Target Oncol; 2019 Apr; 14(2):187-195. PubMed ID: 30887420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Tyrosine Kinase Inhibitor
    Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma.
    Ikeda T; Ishihara H; Takagi T; Kondo T; Yoshida K; Iizuka J; Tanabe K
    Target Oncol; 2018 Jun; 13(3):379-387. PubMed ID: 29785576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis.
    Nearchou A; Valachis A; Lind P; Akre O; Sandström P
    Clin Genitourin Cancer; 2015 Aug; 13(4):280-286. PubMed ID: 25442773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
    Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Liu Y; Zhou L; Chen Y; Liao B; Ye D; Wang K; Li H
    BMC Urol; 2019 Jun; 19(1):49. PubMed ID: 31174518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors.
    Xu X; Wang J; Wang Y; Zhu Y; Wang J; Guo J
    Cell Oncol (Dordr); 2024 Oct; 47(5):1943-1956. PubMed ID: 39222176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.